Study of a new drug for advanced solid tumors that haven't responded to treatment
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have a type of advanced solid tumor that has spread or come back, and that did not respond to at least two previous treatments.
- You must be generally able to do daily activities (ECOG score 0 or 1, meaning you are up and about).
- You must be at least 4 weeks past any chemotherapy, radiation, or surgery, and at least 6 weeks past certain stronger chemotherapy drugs (mitomycin or nitrosoureas).
- Your major organs (like heart, liver, kidneys) must be working well enough, and you cannot have uncontrolled heart problems, active serious infections, autoimmune diseases, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new experimental drug (called NCP-IL-22BP mRNA) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and maybe effective against the cancer.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This trial tests a new type of immunotherapy that is injected directly into a tumor. The treatment uses mRNA (genetic material) wrapped in a fat particle to stimulate your immune system to attack the cancer. It's for people with advanced solid tumors that haven't responded to standard treatments.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Hear when a new Refractory Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.